Noul, an AI-based blood and cancer diagnostics company, announced on the 10th that it has signed a contract to exclusively supply its AI blood analysis solution 'miLab™ BCM' to major Italian hospitals and screening centers for two years, worth $520,000.
Noul previously supplied its malaria diagnostic solution, "miLab MAL," to general hospitals and malaria centers in Italy. Following the successful validation of its "miLab BCM" product, Noul recently signed a new supply agreement. This agreement builds on Noul's confidence in the performance and technological prowess of its products, and the company plans to supply the product to Italy for the next two years.
Noul CEO Chan-Yang Lim said, “As Noul’s flagship products are recognized for their technological prowess and performance in the global market, we are seeing an encouraging trend of contracts with existing partners expanding to include new products. Based on this proven product power and high reliability, we plan to further accelerate our entry into new markets and distribution network expansion within Europe.”
- See more related articles
You must be logged in to post a comment.